- Home
- LPG vs XNCR Comparison
LPG vs XNCR Comparison
Compare LPG & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPG | XNCR |
|---|---|---|
| Founded | 2013 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | LPG | XNCR |
|---|---|---|
| Price | $27.99 | $14.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $35.00 | $22.78 |
| AVG Volume (30 Days) | 488.1K | ★ 779.7K |
| Earning Date | 01-30-2026 | 02-26-2026 |
| Dividend Yield | ★ 12.04% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.23 | N/A |
| Revenue | ★ $359,008,462.00 | $150,132,000.00 |
| Revenue This Year | $26.79 | $18.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.94 | ★ N/A |
| Revenue Growth | N/A | ★ 38.16 |
| 52 Week Low | $16.66 | $6.92 |
| 52 Week High | $32.79 | $24.66 |
Technical Indicators
Market Signals| Indicator | LPG | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 73.04 | 44.68 |
| Support Level | $23.86 | $13.77 |
| Resistance Level | $24.45 | $15.42 |
| Average True Range (ATR) | 0.71 | 0.76 |
| MACD | 0.40 | -0.20 |
| Stochastic Oscillator | 95.58 | 35.90 |
Price Performance
Historical ComparisonAbout LPG Dorian LPG Ltd.
Dorian LPG Ltd is an international liquefied petroleum gas shipping company focused on owning and operating gas carriers, or VLGCs. The company currently owns and operates around 22 modern VLGCs, including nineteen new fuel-efficient 84,000 cbm ECO-design VLGCs. Dorian LPG has offices in Connecticut, USA, London, United Kingdom, and Athens, Greece. IT operates in one reportable segment, the international transportation of LPG.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.